Insilico Medicine announced the nomination of ISM0387 as a preclinical candidate in the United Arab Emirates, marking what the company described as the first UAE-based preclinical candidate to emerge from its generative AI drug discovery platform. The announcement was made jointly with the Emirates Drug Establishment and supported by the Abu Dhabi Investment Office and the Department of Health Abu Dhabi, according to a press release issued via PRNewswire.
The disclosure does not include quantitative preclinical data. No efficacy endpoints, model systems, dosing regimens, pharmacokinetic parameters, or tolerability findings were reported in the available material. The mechanism of action, biological target, and therapeutic indication for ISM0387 remain undisclosed, as does any timeline for investigational new drug filing or entry into clinical testing.
Findings are limited to the announcement of candidate nomination. No animal or cell-based study results were reported, no human data were presented, and the company did not disclose the preclinical package supporting the nomination. Preclinical candidate nomination is an early internal milestone that does not, by itself, establish therapeutic activity, safety margins, or translational readiness. Preclinical findings, when they are disclosed, may not translate to clinical outcomes.
Insilico Medicine has previously advanced candidates generated through its generative AI platform into clinical development, including ISM001-055 for idiopathic pulmonary fibrosis, which reached phase II testing. Whether ISM0387 will follow a similar trajectory cannot be assessed from the information currently available.
Spot something wrong? Report an issue with this article